O'Brien succeeds Joseph F. Berardino, who established a solid foundation for the company in its early years by putting the business platform in place to secure funding for the Company. Joe also played a critical role in solidifying partnerships to progress the five technology platforms. The board of directors credits Berardino for the company's emergence as a successful biotechnology business. Berardino will continue with the company as a director.
"I have enjoyed working with the founding scientists, management, board and staff of the company to bring Profectus to where it is today. The opportunities before us are immense and the company is on solid footing to make the most of our science and technology. Shawn is the ideal leader to take the helm as CEO," said Berardino.
In addition, the company's board of directors announced that Donald R. Caldwell will serve as its chairman. Caldwell, who initially joined the Profectus board of directors in June 2007, is founder, chairman and chief executive officer of Cross Atlantic Capital Partners Inc., an international venture capital firm focused on highly innovative technology companies.
Prior to founding Cross Atlantic Capital Partners, Caldwell was
president and chief operating officer of Safeguard Scientifics and served
in a number of executive and financial positions, including chief
administrative officer of a predecessor company of Cambridge Technology
Partners, Inc. and president of Atlantic Financial. Earlier, Caldwell
earned his CPA and was a partner in the national office of Arthur Young &
Co., after receiving his masters of business administration from the
|SOURCE Profectus BioSciences Inc.|
Copyright©2008 PR Newswire.
All rights reserved